SCHEMBL2770063

SCHEMBL2770063

CCOC(=O)Cc1c(C)cn2ccc(C(F)(F)F)cc12

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.38
GRM5 P41594 1/20 0.37
GRIN1 Q05586 2/20 0.37
GRIN2B Q13224 2/20 0.37
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 2/20 0.35
POLB P06746 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HPGD P15428 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PPARG P37231 1/20 0.35
TRPM2 O94759 1/20 0.35
KCNN4 O15554 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2769817 0.82 PPARG (0.38) GRM5L3MBTL1GAAMAPTPOLB
SCHEMBL23639582 0.75 KDM4E (0.50) GRM5ALDH1A1L3MBTL1MAPTPOLB
SCHEMBL2769389 0.74 MAPT (0.39) GRM5ALDH1A1L3MBTL1GAAMAPT
SCHEMBL4636895 0.72 KCNN4 (0.39) GRM5GRIN1GRIN2BALDH1A1L3MBTL1
SCHEMBL24651096 0.71 POLB (0.45) ALDH1A1L3MBTL1GAAMAPTPOLB
SCHEMBL18366192 0.69 MAPT (0.46) GRM5GRIN1GRIN2BALDH1A1L3MBTL1
SCHEMBL701131 0.68 ALDH1A1 (0.61) ALDH1A1L3MBTL1MAPTPOLBSMN1; SMN2
SCHEMBL2774909 0.68 KDM4E (0.40) GRM5ALDH1A1L3MBTL1GAAMAPT
SCHEMBL11252096 0.68 MAPT (0.55) GSRALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL23218135 0.67 ANO1 (0.45) ALDH1A1L3MBTL1GAAMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910357-B1 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LTD (GB) 2010-04-14 EP disclosed
US-20090163534-A1 Indolizine Derivatives ARGENTA DISCOVERY LIMITED (GB) 2009-06-25 US disclosed
CN-101243086-A Indolizine derivatives and their use as CRTH2 antagonists ARGENTA DISCOVERY LTD (GB) 2008-08-13 CN disclosed
EP-1910357-A2 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS Argenta Discovery Limited (GB) 2008-04-16 EP disclosed
WO-2006136859-A2 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163534-A1 Indolizine Derivatives HRH4, HRH2, NR1H2 GSR 1101/4885GRM5 143/4885GRIN1 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.